Colchicine in Patients with Chronic Coronary Disease
In a randomized trial involving patients with chronic coronary disease, the risk of cardiovascular events was significantly lower among those who received 0.5 mg of colchicine o...
Publications
View AllAdjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free surviv...
Affiliated Researchers
Institution Info
- Type
- healthcare
- Country
- AU
- Publications
- 2
- Citations
- 3,590
External Links
Identifiers
- ROR
- https://ror.org/027p0bm56